PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models-Reference-Cited by-同舟云学术

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Published:2015-07 Issue:1 Volume:28 Page:70-81
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Zou Helen Y.,Friboulet Luc,Kodack David P.,Engstrom Lars D.,Li Qiuhua,West Melissa,Tang Ruth W.,Wang Hui,Tsaparikos Konstantinos,Wang Jinwei,Timofeevski Sergei,Katayama Ryohei,Dinh Dac M.,Lam Hieu,Lam Justine L.,Yamazaki Shinji,Hu Wenyue,Patel Bhushankumar,Bezwada Divya,Frias Rosa L.,Lifshits Eugene,Mahmood Sidra,Gainor Justin F.,Affolter Timothy,Lappin Patrick B.,Gukasyan Hovhannes,Lee Nathan,Deng Shibing,Jain Rakesh K.,Johnson Ted W.,Shaw Alice T.,Fantin Valeria R.,Smeal Tod

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference48 articles.

1. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies;Bagrodia;Pigment Cell Melanoma Res.,2012

2. Taking aim at ALK across the blood-brain barrier;Camidge;J. Thorac. Oncol.,2013

3. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol.,2012

4. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor;Chen;J. Med. Chem.,2013

5. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors;Choi;N. Engl. J. Med.,2010

Cited by 397 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

2. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

3. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

4. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification;Lung Cancer;2024-09

5. AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer;iScience;2024-09